Drug Information

Drug General Information
Drug ID
D0Q7TH
Former ID
DIB008172
Drug Name
BMS-181885
Synonyms
3-[3-[3-[4-(5-Methoxypyrimidin-4-yl)piperazin-1-yl]propyl]-1H-indol-5-ylamino]-4-methyl-3-cyclobutene-1,2-dione
Indication Migraine [ICD9: 346; ICD10:G43] Terminated [546243]
Structure
Download
2D MOL

3D MOL
CAS Number
CAS 165250-52-2
Target and Pathway
Target(s) 5-hydroxytryptamine 1D receptor Target Info Agonist [525577], [551730]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Serotonergic synapse
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT1 type receptor mediated signaling pathway
Reactome Serotonin receptors
G alpha (i) signalling events
WikiPathways Serotonin HTR1 Group and FOS Pathway
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
References
Ref 546243Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007062)
Ref 525577Sensitive triple-quadrupole mass spectrometric assay for the determination of BMS-181885, a 5-HT1 agonist, in human plasma following solid phase extraction. Biomed Chromatogr. 1999 Oct;13(6):425-30.
Ref 551730Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.